Michael J Delves
Overview
Explore the profile of Michael J Delves including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie S, Tai C, Morton C, Ma L, Huang S, Wittlin S, et al.
PLoS Pathog
. 2024 Dec;
20(12):e1012429.
PMID: 39652589
The Plasmodium falciparum cytoplasmic tyrosine tRNA synthetase (PfTyrRS) is an attractive drug target that is susceptible to reaction-hijacking by AMP-mimicking nucleoside sulfamates. We previously identified an exemplar pyrazolopyrimidine ribose sulfamate,...
2.
Sparkes P, Famodimu M, Alves E, Springer E, Przyborski J, Delves M
Commun Biol
. 2024 Nov;
7(1):1525.
PMID: 39550509
Plasmodium male and female gametocytes are the gatekeepers of human-to-mosquito transmission, therefore essential for propagation of malaria within a population. Whilst dormant in humans, their divergent roles during transmission become...
3.
Kumar A, Li Y, Dodean R, Roth A, Caridha D, Madejczyk M, et al.
ACS Infect Dis
. 2024 Nov;
10(12):4291-4300.
PMID: 39526703
Well-tolerated and novel antimalarials that can combat multiple stages of the parasite life cycle are desirable but challenging to discover and develop. Herein, we report results for natural product-inspired novel...
4.
Awalt J, Su W, Nguyen W, Loi K, Jarman K, Penington J, et al.
Eur J Med Chem
. 2024 Oct;
280:116921.
PMID: 39388903
Drug resistance against antimalarials is rendering them increasingly ineffective and so there is a need for the development of new antimalarials. To discover new antimalarial chemotypes a phenotypic screen of...
5.
Dans M, Boulet C, Watson G, Nguyen W, Dziekan J, Evelyn C, et al.
Nat Commun
. 2024 Sep;
15(1):8459.
PMID: 39349462
No abstract available.
6.
Ashton T, Calic P, Dans M, Kang Ooi Z, Zhou Q, Loi K, et al.
ChemMedChem
. 2024 Aug;
19(24):e202400549.
PMID: 39210733
The emergence of resistance against current antimalarial treatments has necessitated the need for the development of novel antimalarial chemotypes. Toward this goal, we recently optimised the antimalarial activity of the...
7.
Ashton T, Calic P, Dans M, Kang Ooi Z, Zhou Q, Palandri J, et al.
J Med Chem
. 2024 Aug;
67(16):14493-14523.
PMID: 39134060
To contribute to the global effort to develop new antimalarial therapies, we previously disclosed initial findings on the optimization of the dihydroquinazolinone-3-carboxamide class that targets PfATP4. Here we report on...
8.
Dans M, Boulet C, Watson G, Nguyen W, Dziekan J, Evelyn C, et al.
Nat Commun
. 2024 Jun;
15(1):5219.
PMID: 38890312
With resistance to most antimalarials increasing, it is imperative that new drugs are developed. We previously identified an aryl acetamide compound, MMV006833 (M-833), that inhibited the ring-stage development of newly...
9.
Li Y, Cardoso-Silva J, Kelly J, Delves M, Furnham N, Papageorgiou L, et al.
Artif Intell Med
. 2024 Jan;
147:102700.
PMID: 38184363
Background: The search for new antimalarial treatments is urgent due to growing resistance to existing therapies. The Open Source Malaria (OSM) project offers a promising starting point, having extensively screened...
10.
Tsebriy O, Khomiak A, Miguel-Blanco C, Sparkes P, Gioli M, Santelli M, et al.
PLoS Pathog
. 2023 Oct;
19(10):e1011711.
PMID: 37801466
Preventing parasite transmission from humans to mosquitoes is recognised to be critical for achieving elimination and eradication of malaria. Consequently developing new antimalarial drugs with transmission-blocking properties is a priority....